Prestige Biopharma Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

0.81

EPS

—

Div Yield, %

—

Shrs. gr., 5y

-27.52%

Rev. gr., 5y

-19.89%

Revenues

689m

+325.77%

Net income

-32.92b

CFO

-48.03b

L-20.32%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

URL

https://www.prestigebiopharma.com/

IPO date

Feb 05, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT